Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo M S, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia M A, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera J A, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera M F, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio J A, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez J L, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila J F, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco J A
Sociedad Española de Beneficencia, Pachuca, Hidalgo, México.
Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
Rev Gastroenterol Mex (Engl Ed). 2019 Jan-Mar;84(1):69-99. doi: 10.1016/j.rgmx.2018.11.007. Epub 2019 Jan 31.
Nonalcoholic fatty liver disease (NAFLD) affects nearly one third of the population worldwide. Mexico is one of the countries whose population has several risk factors for the disease and its prevalence could surpass 50%. If immediate action is not taken to counteract what is now considered a national health problem, the medium-term panorama will be very bleak. This serious situation prompted the Asociación Mexicana de Gastroenterología and the Asociación Mexicana de Hepatología to produce the Mexican Consensus on Fatty Liver Disease. It is an up-to-date and detailed review of the epidemiology, pathophysiology, clinical forms, diagnosis, and treatment of the disease, whose aim is to provide the Mexican physician with a useful tool for the prevention and management of nonalcoholic fatty liver disease.
非酒精性脂肪性肝病(NAFLD)影响着全球近三分之一的人口。墨西哥是其人口具有该疾病多种风险因素的国家之一,其患病率可能超过50%。如果不立即采取行动应对这一目前被视为国家健康问题的情况,中期前景将非常黯淡。这种严峻形势促使墨西哥胃肠病学协会和墨西哥肝病学协会制定了《墨西哥非酒精性脂肪性肝病共识》。它是对该疾病的流行病学、病理生理学、临床类型、诊断和治疗的最新且详细的综述,目的是为墨西哥医生提供一个预防和管理非酒精性脂肪性肝病的有用工具。